+44 (0)24 7671 8970
More publications     •     Advertise with us     •     Contact us
 
Loading...
News Article

New investment in light-powered biosensor accelerates the availability of high quality – low cost tests

News

Surfix announces an investment of € 8,5 million by a Dutch consortium consisting of companies Qurin Diagnostics and LioniX International, industry accelerator PhotonDelta and the East Netherlands Development Agency Oost NL for further development of Surfix’s plug-and-play diagnostics platform.

Surfix will use the investment to accelerate the development of its fast, reliable and attractive plug-and-play diagnostics platform for all sorts of point-of-care tests. The initial target applications are early cancer diagnosis, Covid-19 detection and tracing of pathogens in water for aquaculture.

Low cost tests available for the masses

The global Covid-19 pandemic underlines the need for fast and reliable point-of-care diagnostics anytime and anywhere. Also in areas where there is no hospital, clinic or trained medical staff available. A sample taken from the patient is tested on the spot, next to the hospital bed, in the doctor’s office or even at home. Within minutes the result is visible and appropriate action can be taken. It is convenient, in some cases lifesaving, and there is no time-consuming and expensive laboratory work or equipment involved. The availability of a quick and reliable test would mean a huge step forward in the fight against the current and future pandemics. The ultimate goal for Surfix is to make a test that is available for the masses and at the cost of only a few euros.

Unique diagnostics platform

The biosensor of Surfix consists of two significant elements: the most crucial part is the chip in which the actual sensing occurs. The other part is the microfluidics part, in which the biological assay takes place in a small sample volume.

In the sensing part light passes through the chip (comparable to a minuscule glass-fiber spiral) instead of electricity. Biomolecules attached to the surface of the chip can catch other biomolecules out of a sample (for instance blood or urine), based on biorecognition. This causes a change in the properties of the light that is traveling through the chip, which can be detected and read by the sensor system. This change is a measure of the presence of the biomolecule in the sample one is looking for.

Before entering the sensing part of the sensor, any sample needs to be processed (comparable to a very small laboratory). This takes place in microfluidic channels which feed the sample into the sensing part.

For the sensing part Surfix has developed unique nano-coatings which enable the binding of biomolecules and enhance the sensitivity of the sensor, while the microfluidic part is covered with a different nano-coating that repels biomolecules and enhances the flow of the sample through the microfluidic channels.

The plug-and-play diagnostics platform can be used to detect viruses, DNA and RNA, proteins like antibodies and antigens, and other biomolecules.

Combination of Dutch technology

The plug-and-play diagnostics platform combines LioniX’s integrated photonics chip with Surfix’s nanocoatings for the proper functioning of both the sensing part and the microfluidics part. Integrated photonics is a revolutionary technology that allows the development of chips that can sense, capture and process huge amounts of data with light instead of electricity. Using light means that new types of devices and systems such as biosensors can be created that are radically cheaper, faster, smaller, more robust and reliable while using less energy. Qurin will be the launching customer for the platform in the field of cancer diagnostics in a screening setting on a regular basis for the entire adult population. This way Surfix hopes to contribute to the early detection and cure of the cancer patient. Qurin’s novel biomarker technology aims to detect most if not all cancer types in urine, including lung cancer and cancer of the large bowel.

EMCORE announces integration of PICs into its products
Scottish photonics consortium wins £4.7m in UKRI funding
Yuanjie Semiconductor to supply lasers to POET
Fraunhofer IPMS announces government funding for quantum photonic chip
POET Technologies partners with Yuanjie Semiconductor Technology
SiLC announces silicon photonics systems for machine vision
Scientists develop novel optical modulators for integrated photonics
Scientists report integrated photodiodes on TFLN
Coherent wins award for innovative photonics product
FBH to present quantum technology developments at EQTC 2023
Skorpios and FormericaOE demonstrate PICs in 800G optical transceivers
EFFECT Photonics verifies fully integrated InP PIC
NASA awards grant for silicon photonics project
OpenLight and Spark Photonics partner on PIC design services
DustPhotonics announces 800G chip for hyperscale data centres and AI
Lightwave Logic Receives Industry Innovation Award
Imec announces SiGe BiCMOS optical receiver
SiFotonics announces silicon photonics 800G LPO solutions
Rockley Photonics progresses noninvasive biomarker monitoring
MantiSpectra secures €4 million for miniaturised spectrometers
Sivers to demo next-gen laser arrays at ECOC 2023
ASMPT AMICRA and Teramount collaborate on silicon photonics packaging
Quantum Computing Inc. selects Arizona site for photonic chip foundry
German government to fund ams OSRAM optoelectronic semiconductor development
Luceda Photonics introduces new PIC design software
Vodafone explores silicon photonics for future mobile networks
Coherent introduces 1200 mW pump laser module
Photonics startups invited to apply to Luminate NY accelerator
New tool could improve lithography for smaller, faster chips
InP-based lasers surpass 2.2 mm
Indie Semiconductor buys Exalos AG
New technique controls direction and wavelength of emitted heat

×
Search the news archive

To close this popup you can press escape or click the close icon.
Logo
×
Logo
×
Register - Step 1

You may choose to subscribe to the PIC Magazine, the PIC Newsletter, or both. You may also request additional information if required, before submitting your application.


Please subscribe me to:

 

You chose the industry type of "Other"

Please enter the industry that you work in:
Please enter the industry that you work in: